Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial
Georg Martin Haag, Christoph Springfeld, Barbara Grün, Leonidas Apostolidis, Stefanie Zschäbitz, Mareike Dietrich, Anne-Katrin Berger, Tim Frederik Weber, Inka Zoernig, Marina Schaaf, Lisa Waberer, Daniel Wilhelm Müller, Salah-Eddin Al-Batran, Niels Halama, Dirk Jaeger
Topics & Concepts
MedicinePembrolizumabInternal medicineClinical endpointOncologyAdverse effectSalvage therapyPhases of clinical researchOxaliplatinCommon Terminology Criteria for Adverse EventsMaravirocColorectal cancerGastroenterologySurgeryToxicityCancerClinical trialImmunologyChemotherapyImmunotherapyHuman immunodeficiency virus (HIV)Cancer Immunotherapy and BiomarkersImmune cells in cancerGenetic factors in colorectal cancer